Comparative evaluation of the in-vitro activity of six β-lactam/β-lactamase inhibitor combinations against gram negative bacilli

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 2, 2013, Pages 224-228

  Sood, Smita ^a  

^a FORTIS HOSPITAL   (India)

Author keywords

Gram negative bacilli; lactam lactamase inhibitor combinations

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TAZOBACTAM; TIMENTIN;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COMPARATIVE STUDY; DRUG SCREENING; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KIRBY BAUER METHOD; NONHUMAN; SENSITIVITY ANALYSIS;

EID: 84873673370     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/4564.2733     Document Type: Article

References (27)

1. Pérez-Llarena FJ, Bou G. Beta-Lactamase Inhibitors: The Story so Far. Curr Med Chem. 2009; 16(28):3740-65.
2. Erdal AH. Use of [beta] -Lactam/[beta] -Lactamase Inhibitor Combin-ations to Treat Community-Acquired Respiratory Tract Infections. Infect Dis Clin Pract. 2002; 11: S20-S26.
3. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr Opin Microbiol. 2005; 8 (5):518-24.
4. Drawz SM, Bonomo RA, Three Decades of β-Lactamase. Clin Microbiol Rev. 2010; 23(1): 160-201.
5. Philip D. Lister. β-Lactamase Inhibitor Combinations with Extended-Spectrum Penicillins: Factors Influencing Antibacterial Activity against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacother. 2000; 20: 213S-218S.
6. Bush LM, Johnson CC. Uriedopenicillins and beta-lactam/beta lactamase inhibitor combinations. Infect Dis Clin North Am. 2000; 14(2):409-33.
7. Lee N, Yuen KY, Kumana R. Clinical role of beta lactam/beta lactamse inhibitor combinations. Drugs 2003;63:1511-24.
8. Bauer AW, Kirby WMM, Sherris JC and Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Path. 1966; 45:493-96.
9. Clinical Laboratory Standards Institute. Performance standards for Antimicrobial Susceptibility testing. Twentieth informational supplement. CLSI document M100-S20 Wayne, PA: CLSI; 2010.
10. Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A. Comparative in vitro activity of beta lactam/beta lactamse inhibitor combinations against gram negative bacteria. Ind J Med Res. 2005; 122:425-28.
11. Chitnis SV, Chitnis V, Sharma N, Chitnis DS. Current status of drug resistance among Gram-negative bacilli isolated from admitted cases in a tertiary care centre. J Assoc Phy Ind. 2003; 51: 28-32.
12. Anuradha V, Sailaja V V, Umabala P, Sateesh T, Lakshmmi V. Sensitivity pattern of Gram negative Bacilli to three β-lactam/β-lactamse inhibitor combinations using the automated API system. Ind J Med Microbiol. 2007; 25(3):203-08.
13. Gupta V, Datta P, Agnihotri N, Chander J. Comparative in vitro activities of seven new β-lactams, alone and in combination with β-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins. Braz J of infect Dis. 2006; 10(1):22-25.
14. Prabhash K, Medhekar A, Biswas S, Kurkure P, Nair R, Kelkar R. Comparison of in vitro activities of ceftazidime, piperacillin-tazobactam, and cefoperazone-sulbactam, and the implication on empirical therapy in patients with cancer. Ind J Cancer. 2009; 46:318-22.
15. Ghafur A, Ramasamy P, Sarathy N, Krishnamurthy R, Durairajan S. Sensitivity pattern of Gram negative bacteria to the new β-lactam/ β-lactamase inhibitor combination: Cefepime/tazobactam. J Microbiol Infect Dis. 2012; 2 (1): 5-8.
16. Rani H, Kaistha N, Gupta V, Chander J. Choice of antibiotics in community Acquired UTI due to Escherichia coli in adult age group. J Clin Diag Res. 2011; 5(3):483-85.
17. Pal RB, Pal P, Venkatesh V, Kulkarni KP. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime. J Ind Med Assoc. 2008; 106(9): 605-6, 611.
18. Mulla S, Charan J, Panvala T. Antibiotic sensitivity of Enterobacteriaceae at a tertiary care center in India. Chron Young Sci. 2011; 2:214-18.
19. Pal RB, Rodrigues M. Incidence of β-lactamase producing organisms causing various infections and comparison of their antimicrobial susceptibility testing. Int J Appl Biol Pharma Technol. 2010; 1(3): 1322-29.
20. Samanta P, Gautam V, Thapar R, Ray P. Emerging resistance of non-fermenting gram negative bacilli in a tertiary care centre. Ind J Pathol Microbiol. 2011; 54:666-67.
21. Hassan A, Usman J, Kaleem F, Khan A, Hussain Z. In vitro activity of aminoglycosides, β lactam-β lactamases inhibitor combinations and tetracyclines against multi-drug resistant Acinetobacter baumannii. J Microbiol Antimicrob. 2010; 2(4), 47-50.
22. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007; 7:338-48.
23. Chaudhuri BN, Rodrigues C, Balaji V, Iyer R, Sekar U, Wattal C, Chitnis DS, Dhole TN, Joshi S. Incidence of ESBL Producers amongst Gram-negative Bacilli Isolated from Intra-abdominal Infections across India (Based on SMART Study, 2007 Data). JAPI. 2011; 59:1-6.
24. Livermore DM. Has the era of untreatable infections arrived? Antimicrob Chemother. 2009; 64 (Suppl 1): i29-i36.
25. Prakash S. Carbapenem sensitivity profile among bacterial isolates from clinical specimens from Kanpur City. Ind J Crit Care Med. 2006; 10(4):2500-03.
26. Gupta E, Mohanty M, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Ind J Med Res. 2006; 124: 95-98.
27. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic Options for Infections with Enterobacteriaceae Producing Carbapenem-hydrolyzing Enzymes. Future Microbiol. 2011; 6(6):653-66.